Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBIONASDAQ:COCPNASDAQ:ODTNASDAQ:ONCSNASDAQ:XCUR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsCOCPCocrystal Pharma$1.47+2.8%$1.49$1.33▼$3.29$14.95M1.3413,756 shs5,066 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsXCURExicure$0.58-3.3%$0.62$0.36▼$1.50$5.01M1.31406,916 shs23,881 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,163.62%COCPCocrystal Pharma-2.05%-8.92%-3.38%-7.74%-44.49%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-73.09%XCURExicure-6.62%-4.21%-9.38%-4.29%-46.30%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma2.5303 of 5 stars3.53.00.00.00.01.71.3ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AXCURExicure2.9046 of 5 stars0.04.00.04.72.61.71.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCatalyst BiosciencesN/AN/AN/AN/ACOCPCocrystal Pharma3.00Buy$10.00580.27% UpsideODTOdonate TherapeuticsN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AXCURExicureN/AN/AN/AN/ACurrent Analyst RatingsLatest CBIO, ONCS, XCUR, ODT, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00COCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AXCURExicure$28.83M0.17N/AN/A$3.00 per share0.19Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/ACOCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)ODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/AXCURExicure-$2.58M$1.680.34∞N/AN/AN/AN/A7/12/2024 (Estimated)Latest CBIO, ONCS, XCUR, ODT, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCatalyst BiosciencesN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCatalyst BiosciencesN/A2.882.88COCPCocrystal PharmaN/A8.928.92ODTOdonate TherapeuticsN/AN/AN/AONCSOncoSec MedicalN/A0.890.89XCURExicureN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCatalyst Biosciences5.98%COCPCocrystal Pharma6.72%ODTOdonate TherapeuticsN/AONCSOncoSec Medical8.69%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipCBIOCatalyst Biosciences2.92%COCPCocrystal Pharma25.06%ODTOdonate Therapeutics48.90%ONCSOncoSec Medical1.32%XCURExicure3.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableXCURExicure78.65 million8.31 millionNot OptionableCBIO, ONCS, XCUR, ODT, and COCP HeadlinesSourceHeadlineExicure gets grant for liposomal particles for gene regulation with spherical geometrypharmaceutical-technology.com - April 18 at 9:05 AMExicure (NASDAQ:XCUR) Shares Down 8.7% americanbankingnews.com - April 18 at 1:34 AMExicure Stock (NASDAQ:XCUR), Short Interest Reportbenzinga.com - February 22 at 7:55 AMExicure inks licensing deal for one of its remaining therapieschicagobusiness.com - February 12 at 7:43 AMWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com - February 6 at 2:15 PMWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarketmsn.com - February 6 at 9:44 AMExicure Inc Announces Licensing Patents for Therapeutic Advancementmsn.com - February 6 at 9:15 AMExicure, Inc. and Bluejay Therapeutics Inc. Enter…pharmiweb.com - February 5 at 10:23 PMExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis Treatmentmarketwatch.com - February 5 at 5:22 PMExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitisfinance.yahoo.com - February 5 at 5:22 PMBest Undervalued Stocks for February 2024msn.com - February 1 at 1:04 PMExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo Financeca.finance.yahoo.com - December 16 at 8:49 AMWhy Is Exicure (XCUR) Stock Up 57% Today?investorplace.com - December 8 at 10:01 AMExicure: Nonreliance On Previously Issued Financial Statements Or A Related Audit Report Or Completed Interim Reviewcbonds.com - December 3 at 8:28 AMExicure receives Nasdaq delinquency notice on late filing of its form 10-Qmsn.com - November 28 at 5:18 PMExicure Inc XCURmorningstar.com - November 9 at 1:25 PMLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Dropfinance.yahoo.com - August 29 at 7:04 AMExicure names new CEO, CFO, directors in wake of resignationsmsn.com - August 23 at 4:05 PMExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)finance.yahoo.com - August 15 at 7:28 AMExicure: Substantial Financing Needed to Continue Operationsmarketwatch.com - August 11 at 5:38 PMExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updatebusinesswire.com - August 11 at 5:38 PMExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - July 14 at 6:09 PMExicure board backs CEO Kim's strategic alternative view for companymsn.com - May 26 at 5:52 PMExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternativesfinance.yahoo.com - May 26 at 5:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCatalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Odonate TherapeuticsNASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.ExicureNASDAQ:XCURExicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.